A high throughput method for Monitoring of Sorafenib, regorafenib, cabozantinib and their metabolites with UPLC-MS/MS in rat plasma

As multi-targeted tyrosine kinase inhibitors, sorafenib, regorafenib and cabozantinib are widely used in hepatocellular carcinoma (HCC) for systemic therapies with anti-proliferative and anti-angiogenic effects. Nevertheless, adverse effects or insufficient efficacy appear frequently due to the plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Er-Min, Liu, Ya-Nan, Pan, Lvjun, Hu, Yingying, Ye, Xuemei, Luo, Pingping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493307/
https://www.ncbi.nlm.nih.gov/pubmed/36160432
http://dx.doi.org/10.3389/fphar.2022.955263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493307/
https://www.ncbi.nlm.nih.gov/pubmed/36160432
http://dx.doi.org/10.3389/fphar.2022.955263

Ejemplares similares